Table of Contents

Psoriasis affects over 7.5 million people in the US, causing inflamed, scaly skin patches that can be painful and persistent. While some manage symptoms with creams or pills, moderate to severe cases often require stronger treatments. Injections provide a more targeted approach, helping to reduce inflammation and slow excessive skin cell growth.

This guide explores several injections for psoriasis that can be self-administered at home, making long-term treatment more manageable. We’ll cover how they work, dosing frequency, and key factors to consider when choosing a treatment.

Key Takeaways

    • Injections for psoriasis are highly effective for moderate to severe cases, offering significant symptom relief.
    • Different drug classes target different inflammatory pathways. TNF blockers suppress general inflammation, while newer IL-12, IL-17, and IL-23 inhibitors offer more precise mechanisms with potentially fewer side effects.
    • Dosing frequency varies widely among injections. Some require frequent injections (weekly or biweekly), while others need only four injections per year after the initial doses, making adherence easier for some patients.
    • Most biologic injections for psoriasis demonstrate high PASI 75, 90, and even 100 rates, meaning they significantly reduce psoriasis severity, with some achieving near-complete skin clearance in long-term studies.
    • Many psoriasis injections are also used to treat psoriatic arthritis, Crohn’s disease, or ulcerative colitis, making them beneficial for patients with overlapping conditions.

7 FDA-Approved Injections for Psoriasis

Several injections for psoriasis are available, each with distinct characteristics:

1. Humira

Humira injections for psoriasis

Active Ingredients: Adalimumab

Drug Class: Tumor Necrosis Factor (TNF) Blocker

Dosage Form and Strength: 

    • Humira Pen: 80 mg and 40 mg
    • Prefilled Syringe: 80 mg, 40 mg, 20 mg, and 10 mg

Dosage Frequency for Psoriasis: Once every 2 weeks

Common Side Effects: Infections (e.g. upper respiratory, sinusitis), injection site reactions, headache, and rash.

Approved Indications:

    • Rheumatoid Arthritis
    • Polyarticular Juvenile Idiopathic Arthritis in patients 2+
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Crohn’s Disease in adults and children 6+
    • Ulcerative Colitis in adults and children 5+
    • Plaque Psoriasis
    • Hidradenitis Suppurativa in patients 12+
    • Non-infectious Uveitis in adults and children 2+

PROS:

  • Convenient self-injection
  • Also approved for Crohn’s disease and ulcerative colitis, which can coexist with psoriasis
  • Available patient assistance programs
  • Has multiple FDA-approved biosimilars

CONS:

  • Increased infection risk
  • Possible neurological side effects and cancer risk

How does Humira work for Psoriasis?

Humira (adalimumab) is a biologic injection for psoriasis that blocks TNF-alpha, a protein that causes inflammation and rapid skin cell growth in psoriasis. By reducing TNF-? activity, it helps clear plaques, easing redness, scaling, and thickening.

Is Humira effective for Psoriasis?

A real-world study on Humira’s effectiveness in psoriasis showed that 84% of patients achieved PASI 75 (a 75% reduction in psoriasis severity) after 12 months. After 8 years, 88% maintained these results, demonstrating long-lasting benefits.

Another study examined how well Humira treats moderate to severe plaque psoriasis on the hands and feet and whether its effects last. At week 16, 31% of patients on Humira had clear or almost clear skin. Among those who improved, 80% maintained their results for up to 28 weeks.

2. Enbrel

Enbrel injections for psoriasis

Active Ingredients: Etanercept

Drug Class: Tumor Necrosis Factor (TNF) Blocker

Dosage Form and Strength: 

    • Prefilled Syringe: 25 mg and 50 mg
    • SureClick® Autoinjector: 50 mg
    • Single-dose Vial: 25 mg
    • Multiple-dose Vial for reconstitution: 25 mg
    • Enbrel Mini® cartridge for use with the AutoTouch®: 50 mg

Dosage Frequency for Psoriasis:

    • For adults: Twice-weekly injections for the first 12 weeks, followed by a maintenance dose once weekly.
    • For pediatric patients: Once weekly

Common Side Effects: Infections and injection site reactions

Approved Indications: 

    • Rheumatoid Arthritis
    • Polyarticular Juvenile Idiopathic Arthritis in patients 2+
    • Psoriatic Arthritis in adults and children 2+
    • Ankylosing Spondylitis
    • Plaque Psoriasis in adults and children 4+

PROS:

  • Approved for children 4+
  • Self-injectable convenience
  • Long-term management
  • Available support programs to lower costs
  • Has two FDA-approved biosimilars

CONS:

  • Possible nerve-related side effects
  • More prone to infections and boxed warning for cancer risk

How does Enbrel work for Psoriasis?

Enbrel (etanercept) is a biologic medication for plaque psoriasis that is used when topical treatments or phototherapy are not effective. It blocks TNF-alpha, a protein that causes inflammation and excessive skin cell growth, helping to reduce redness, scaling, and plaque thickening.

Is Enbrel effective for Psoriasis?

Both continuous and intermittent use of Enbrel injections for psoriasis helped reduce symptoms in real-world settings. In both groups, PASI scores (which measure psoriasis severity) dropped by 9.5-10 points, and the affected skin area shrank by 12% on average.

Patients new to Enbrel also reported a significant improvement in quality of life, with DLQI scores (measures how much psoriasis affects daily life) decreasing by 5.8 points.

A separate study focused on children with plaque psoriasis. By week 16:

    • 90.7% of children had at least a 50% improvement (PASI 50)
    • 79.1% reached PASI 75, indicating a strong response.
    • 46.5% achieved PASI 90, meaning nearly clear skin.
    • BSA scores dropped significantly, meaning less of the body was affected

Additionally, the CDLQI score dropped from 17.4 to 5.4, showing that children experienced much less impact from psoriasis after treatment with Enbrel.

3. Stelara

Stelara injections for psoriasis

Active Ingredients: Ustekinumab

Drug Class: Interleukin-12 and -23 Antagonist

Dosage Form and Strength: 

    • Prefilled Syringe: 45 mg and 90 mg
    • Single-dose Vial: 45 mg

Dosage Frequency for Psoriasis:

    • For adults and pediatric patients: Initial dose at week 0, followed by another dose at week 4, and then every 12 weeks thereafter.

Common Side Effects: Nasopharyngitis, upper respiratory tract infection, headache, and fatigue.

Approved Indications:

    • Psoriatic Arthritis in adults and children 6+
    • Crohn’s Disease
    • Ulcerative Colitis
    • Plaque Psoriasis in adults and children 6+

PROS:

  • Approved for children 6+
  • Also approved for Crohn’s disease and ulcerative colitis, which can overlap with psoriasis
  • Self-injectable convenience
  • Infrequent dosing (every 12 weeks) after initial doses
  • Available support programs to lower costs
  • Has multiple FDA-approved biosimilars

CONS:

  • Still increases infection risk (though lower than TNF inhibitors)
  • Possible increased risk of certain cancers (under study)
  • Rare neurological risk

How does Stelara work for Psoriasis?

Stelara (ustekinumab) blocks interleukin-12 (IL-12) and interleukin-23 (IL-23), two cytokines that drive inflammation and excessive skin cell growth in psoriasis. By inhibiting these proteins, Stelara reduces inflammation, slows rapid skin cell production, and clears psoriasis symptoms.

Is Stelara effective for Psoriasis?

A study on actual patient experiences showed that at the 16-week mark:

    • 97% of the patients had at least a PASI50 response (50% symptom improvement)
    • 57.6% reached PASI75 (75% improvement)
    • 33.3% achieved PASI90 (90% or near-complete clearance)

These improvements continued over time, with similar response trends observed at 28, 52, 76, and 100 weeks. No major safety concerns were reported, reinforcing Stelara’s effectiveness and safety as a long-term psoriasis treatment.

Another study examined Stelara’s effectiveness in patients with inflammatory bowel disease (IBD) who were also receiving treatment for psoriasis or psoriatic arthritis. Since psoriasis and IBD share common inflammatory pathways, having one condition may increase the risk of developing the other.

In this study, 60.7% of patients achieved clinical remission by their last follow-up visit (average of 10.7 months). The probability of remission was estimated at 84.7% at 6 months and 63.9% at 12 months. These findings suggest that Stelara may be a valuable treatment option for patients with coexisting inflammatory diseases.

4. Cosentyx

Cosentyx injection for psoriasis

Active Ingredients: Secukinumab

Drug Class: Interleukin-17A Antagonist

Dosage Form and Strength: 

    • UnoReady® Pen: 300 mg
    • Prefilled Syringe: 75 mg, 150 mg, and 300 mg
    • Sensoready® Pen: 150 mg

Dosage Frequency for Psoriasis: 

    • For adults and pediatric patients: Initial dose at weeks 0, 1, 2, 3, and 4, followed by a maintenance dose every 4 weeks.

Common Side Effects: Nasopharyngitis, diarrhea, and upper respiratory tract infection.

Approved Indications:

    • Psoriatic Arthritis in adults and children 2+
    • Ankylosing Spondylitis
    • Non-radiographic Axial Spondyloarthritis
    • Enthesitis-related Arthritis in adults and children 4+
    • Plaque Psoriasis in adults and children 6+
    • Hidradenitis Suppurativa

PROS:

  • Approved for pediatric plaque psoriasis
  • Easy at-home self-injection
  • Dosed every 4 weeks after initial injections
  • Cost-saving support programs available
  • No black box warning (serious safety warning) like some other biologic drugs

CONS:

  • No FDA-approved biosimilars yet
  • May increase the risk of inflammatory bowel disease (IBD) or worsen existing Crohn’s disease or ulcerative colitis
  • Risk of infections

How does Cosentyx work for Psoriasis?

Cosentyx (secukinumab) blocks interleukin-17A (IL-17A), a protein that triggers inflammation and causes excessive skin cell growth in psoriasis. By stopping IL-17A, Cosentyx reduces inflammation, slows down rapid skin cell turnover, and helps clear psoriasis plaques.

Is Cosentyx effective for Psoriasis?

The most recent real-world study on Cosentyx injection for psoriasis found that 54-65% of patients achieved PASI90 (90% skin clearance) by Week 24, and 46-63% maintained this response at Week 52. Additionally, 43-47% of patients had nearly clear skin (PASI less than or equal to 1) by Week 12, with 47-56% maintaining this level at Week 52.

Building on these findings, another study directly compared Cosentyx to other biologics and conventional systemic therapies for chronic plaque psoriasis in real-world clinical settings.

Here are the results:

Treatment Group % of patients who achieved PASI90 at month 3 % of patients who achieved PASI90 at month 12
Cosentyx 59.7% 60.8%
Conventional systemic therapies 18.8% 35.3%
Other biologics 40.0% 50.0%

A separate real-world study, based on US dermatology electronic medical records, assessed long-term patient satisfaction with Cosentyx. At six months, 82.3% of patients agreed that the treatment was effective, and satisfaction remained stable at 12 months (81.7%), 18 months (83.3%), and 24 months (81.4%).

5. Taltz

Taltz injection for psoriasis

Active Ingredients: Ixekizumab

Drug Class: Interleukin-17A Antagonist

Dosage Form and Strength:

    • Prefilled Autoinjector: 80 mg
    • Prefilled Syringe: 20 mg, 40 mg, 80 mg

Dosage Frequency for Psoriasis:

    • For adults: Initial doses are given every two weeks for the first 12 weeks, followed by a maintenance dose every 4 weeks.
    • For pediatric patients: Initial dose at week 0, followed by a maintenance dose every 4 weeks.

Common Side Effects: Injection site reactions, upper respiratory tract infections, nausea, and tinea infections.

Approved Indications:

    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Non-radiographic Axial Spondyloarthritis
    • Plaque Psoriasis in adults and children 6+

PROS:

  • Approved for children 6 years older
  • Convenient self-injection at home
  • Maintenance dose once a month
  • Financial assistance programs available
  • No black box warning (serious safety warning) like some other biologic drugs

CONS:

  • Higher risk of tinea infections (e.g. ringworm, athlete’s foot, jock itch, scalp ringworm, and onychomycosis)
  • No FDA-approved biosimilars yet
  • May increase the risk of inflammatory bowel disease (IBD) or worsen existing Crohn’s disease or ulcerative colitis

How does Taltz work for Psoriasis?

Taltz (ixekizumab) works like Cosentyx for psoriasis. It blocks interleukin-17A (IL-17A), a protein that causes inflammation and excessive skin cell growth in psoriasis. By targeting IL-17A, Taltz reduces inflammation, slows down rapid skin turnover, and helps clear psoriasis plaques.

Is Taltz effective for Psoriasis?

A study using data from the US Taltz Customer Support Program found that by week 24, 63.1% had significant itch relief, 64.8% had less pain, and nearly 80% had psoriasis covering only 2% or less of their body, compared to 34.5% at the start.

In another study, researchers analyzed treatment survival with Taltz. Results showed that by week 16, the percentage of patients achieving:

    • PASI100 (complete skin clearance): 54.1%
    • PASI90 (90% improvement): 60.5%
    • PASI less than or equal to 3 (minimal disease): 73%

By week 260 (five years), these numbers improved further:

    • PASI100: 59.1%
    • PASI90: 81.8%
    • PASI less than or equal to 3: 95.5%

These findings confirm that Taltz provides strong and lasting effectiveness for psoriasis treatment.

6. Tremfya

Tremfya shots for psoriasis

Active Ingredients: Guselkumab

Drug Class: Interleukin-23 Antagonist

Dosage Form and Strength: 

    • One-Press Injector: 100 mg
    • Prefilled Syringe: 100 mg and 200 mg
    • Tremfya Pen: 200 mg

Dosage Frequency for Psoriasis: Initial dose given at weeks 0 and 4, followed by a maintenance dose every 8 weeks.

Common Side Effects: Upper respiratory infections, headache, injection site reactions, joint pain, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Approved Indications:

    • Psoriatic Arthritis
    • Ulcerative Colitis
    • Plaque Psoriasis

PROS:

  • Convenient self-injection at home
  • Long dosing interval for maintenance dose (once every two months)
  • Financial assistance programs available
  • No black box warning for cancer risk

CONS:

  • Higher risk of tinea infections (e.g. ringworm, athlete’s foot, jock itch, scalp ringworm, and onychomycosis)
  • Higher risk of herpes simplex infections (e.g. oral herpes, genital herpes, and nasal herpes simplex)
  • No FDA-approved biosimilars yet

How does Tremfya work for Psoriasis?

Tremfya (guselkumab) is a relatively new psoriasis injection treatment with an ongoing FDA review for pediatric psoriasis and juvenile psoriatic arthritis. It is considered the first monoclonal antibody to selectively target the p19 subunit of IL-23, which sets it apart from older IL-23 and IL-12/23 inhibitors.

Before Tremfya, Stelara was the first biologic to target IL-23, but it also blocked IL-12 by binding to their shared p40 subunit. Tremfya was the first biologic to exclusively target IL-23 by binding to its p19 subunit, which is more specific to psoriasis-related inflammation.

Is Tremfya effective for Psoriasis?

A study in real-world settings looked at people with mild, moderate, and severe psoriasis in the US and Canada who started Tremfya treatment between July 2017 and July 2019. After 9-12 months of Tremfya treatment:

    • 64.6% had minimal or no psoriasis, while 36.2% had completely clear skin
    • 61.5% achieved PASI 75 (75% improvement in psoriasis severity)
    • Nearly 37% had completely clear skin (PASI 100)

In another study, researchers examined patients who previously failed anti-IL-17 treatments (like Cosentyx or Taltz). At 16 weeks:

    • 60.7% achieved PASI 90 (90% improvement in psoriasis severity)
    • 37.7% achieved PASI 100 (completely clear skin)

At 2 years (104 weeks):

    • 73.8% had PASI 90
    • 59.0% had PASI 100

Hard-to-treat areas like the scalp, palms/soles, fingernails, and genitals also improved by week 28. Only one patient (1.6%) had primary treatment failure (Tremfya did not work at all), and no severe side effects were reported.

7. Skyrizi

Skyrizi injections for psoriasis

Active Ingredients: Risankizumab-rzaa

Drug Class: Interleukin-23 Antagonist

Dosage Form and Strength: 

    • Prefilled Syringe: 90 mg and 150 mg
    • Prefilled Pen: 150 mg

Dosage Frequency for Psoriasis: Initial dose given at weeks 0 and 4, followed by a maintenance dose every 12 weeks thereafter.

Common Side Effects: Upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

Approved Indications:

    • Psoriatic Arthritis
    • Plaque Psoriasis
    • Crohn’s Disease
    • Ulcerative Colitis

PROS:

  • Requires only four injections per year after the initial two doses
  • Does not pose a known risk of cancer or potential nerve damage
  • Also approved for Crohn’s disease and ulcerative colitis, which can coexist with psoriasis
  • Convenient self-injection
  • Available patient assistance programs

CONS:

  • Higher risk of tinea infections (e.g. ringworm, athlete’s foot, jock itch, scalp ringworm, and onychomycosis)
  • Does not have a biosimilar available yet
  • Limited long-term safety data (over 10+ years)

How does Skyrizi work for Psoriasis?

Skyrizi (risankizumab-rzaa) is among the newer medicines for plaque psoriasis. It works by targeting interleukin-23 (IL-23), similar to how Tremfya works. By blocking IL-23, Skyrizi helps reduce excessive skin cell growth and inflammation, leading to clearer skin and long-lasting symptom relief.

Is Skyrizi effective for Psoriasis? 

Researchers analyzed past medical records of patients with very severe plaque psoriasis who were treated with Skyrizi. The results showed that Skyrizi is highly effective. By week 40, all patients (100%) achieved PASI 75, meaning a 75% improvement in psoriasis severity. By week 104, all patients (100%) reached PASI 90, showing a 90% improvement.

Another study examined Skyrizi’s effectiveness for plaque psoriasis in difficult-to-treat areas, including the scalp, palms, soles, nails, and genital region. These areas are often resistant to treatment.

After one year, most patients achieved clear or almost clear skin based on the Physician’s Global Assessment (PGA).

Affected Area Percentage of Patients Achieving PGA 0 or 1 (Clear/Almost Clear)
Scalp 97.58%
Palms/Soles 95.28%
Genitals 100% (All patients cleared)
Nails 82%

In terms of drug survival rate, a real-world study found that 90.73% of patients were still using Skyrizi after three years. This suggests high patient satisfaction and tolerability. The study also showed that all patients (100%) had clear or almost clear skin in hard-to-treat areas after three years.

Summary

Each FDA-approved injection for psoriasis has its strengths and trade-offs. Humira and Enbrel, as TNF blockers, are well-established but come with a higher infection risk. Stelara, Cosentyx, and Taltz target interleukins, offering better skin clearance with less frequent dosing.

Newer IL-23 inhibitors like Tremfya and Skyrizi require fewer injections and show long-term effectiveness, but their long-term safety is still being studied.

Choosing the right treatment depends on its dosing schedule, effectiveness, and potential side effects. Each option has pros and cons, so discussing it with your doctor is the best way to decide.

Frequently Asked Questions

A steroid injection for psoriasis helps manage symptoms by reducing inflammation and suppressing the immune system’s overactive response that triggers psoriasis flare-ups. The injection, typically containing corticosteroids like triamcinolone (Kenalog), is injected directly into the plaque (intralesional injection). It provides localized relief with fewer systemic side effects compared to oral steroids. However, because improper injection can lead to skin thinning, atrophy, or depigmentation, it should only be done by a trained professional.

Cortisone injections can be highly effective. However, their use is limited due to potential side effects, including skin thinning, atrophy, or discoloration at the injection site. Because of these risks, they are usually reserved for thick, resistant plaques or psoriatic arthritis, rather than widespread psoriasis. They provide localized relief but are not a long-term solution for managing the condition systemically.

Yes. If you have thick, stubborn psoriasis plaques on your scalp, your dermatologist may administer corticosteroid injections directly into the plaques to provide targeted relief. However, this treatment is generally reserved for severe or persistent cases rather than as a first-line option.

Injectable medications for psoriasis, such as biologics, are highly effective and can help you achieve nearly clear skin. However, the “best” option depends on individual factors and should be determined by your doctor. Each injection has a different dosing schedule and potential side effects, so the most suitable choice varies for each person. Your dermatologist can assess your medical history, disease severity, and insurance coverage to recommend the right treatment for you.

Several oral medications are available to treat psoriasis, mainly for moderate to severe cases or when topical treatments aren’t enough. These include apremilast (Otezla), methotrexate (Trexall), cyclosporine (Neoral), acitretin (Soriatane), and deucravacitinib (Sotyktu). These medications vary in effectiveness, side effects, and suitability based on individual health conditions.

The most common side effects of psoriasis injections are injection site reactions (such as redness, swelling, or pain at the injection site) and increased risk of infections (due to the immune-suppressing effects). These are the most frequently reported side effects, but most people experience only mild reactions.

Yes, infusions for psoriasis can be an effective treatment option, especially if you have moderate to severe psoriasis that hasn’t responded well to other treatments. For example, infliximab (Remicade) works similarly to Humira and Enbrel as a TNF blocker. However, unlike these options, Remicade is only available as an intravenous (IV) infusion and cannot be taken as an injection. It is administered in a medical facility, typically every six to eight weeks after an initial loading phase.

The latest FDA-approved medication for plaque psoriasis is bimekizumab (Bimzelx), approved in October 2023. It is a biologic injection that blocks both IL-17A and IL-17F, key inflammatory proteins involved in psoriasis. Clinical trials have shown high skin clearance rates and long-lasting results. Other recent advancements include deucravacitinib (Sotyktu), a TYK2 inhibitor taken as a pill, offering an alternative for those who prefer oral treatment.

To get a prescription for psoriasis treatment, you need to consult a doctor, preferably a dermatologist. They will evaluate your condition, discuss symptoms, and determine the most suitable treatment based on the severity of your psoriasis and medical history. If needed, they may perform tests or a skin biopsy.

For mild to moderate psoriasis, the most common are topical corticosteroids, as they effectively reduce inflammation, redness, and itching. They are available in various strengths and are often used alongside vitamin D analogs (e.g., calcipotriene) to enhance results. For moderate to severe cases, when topical treatments are not sufficient, systemic medications such as methotrexate, cyclosporine, or biologic therapies may be recommended.

Related Articles

Sources

Armstrong, A. W., Mehta, M. D., Schupp, C. W., Gondo, G. C., Bell, S. J., & Griffiths, C. E. M. (2021). Psoriasis prevalence in adults in the United States. JAMA Dermatology, 157(8), 940. https://doi.org/10.1001/jamadermatol.2021.2007

Kojanova, M., Cetkovska, P., Strosova, D., Fialova, J., Arenberger, P., Dolezal, T., & Gkalpakiotis, S. (2021). Real-World evidence from more than 1000 patients treated with adalimumab for Moderate-to-Severe psoriasis in the Czech Republic. Dermatology and Therapy, 11(2), 543–553. https://doi.org/10.1007/s13555-021-00499-8

Leonardi, C., Langley, R. G., Papp, K., Tyring, S. K., Wasel, N., Vender, R., Unnebrink, K., Gupta, S. R., Valdecantos, W. C., & Bagel, J. (2010). Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet. Archives of Dermatology, 147(4), 429. https://doi.org/10.1001/archdermatol.2010.384

AbbVie Inc. (2024). HIGHLIGHTS OF PRESCRIBING INFORMATION OF HUMIRA. https://www.rxabbvie.com/pdf/humira.pdf

Rigopoulos, D., Patsatsi, A., Antoniou, C., Sotiriadis, D., Schulze, A. R., Boubouchairopoulou, N., Skiadas, I., Tsekouras, V., & Hernandez Daly, A. C. (2022). Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexibledosing etanercept in patients with plaque psoriasis in Greece. Dermatology reports, 14(4), 9265. https://doi.org/10.4081/dr.2022.9265

Narbutt, J., Jakubczak, Z., Wasiewicz-Ciach, P., Wojtania, J., Krupa, K., Sobolewska-Sztychny, D., Ci??y?ska, M., Ko?t-Kami?ska, M., Reich, A., Skibi?ska, M., & Lesiak, A. (2024). Effectiveness and Safety of Etanercept in Paediatric Patients with Plaque-Type Psoriasis: Real-World Evidence. Journal of Clinical Medicine, 13(16), 4858. https://doi.org/10.3390/jcm13164858

Immunex Corporation. (2024). HIGHLIGHTS OF PRESCRIBING INFORMATION OF ENBREL. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Enbrel/enbrel_pi_CURNT.pdf

Egeberg, A., Thyssen, J. P., Burisch, J., & Colombel, J. (2018). Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis—A Nationwide 20-Year Cohort Study. Journal of Investigative Dermatology, 139(2), 316–323. https://doi.org/10.1016/j.jid.2018.07.029

Acer, E., ??rek, A., Erdo?an, H. K., & Saraco?lu, Z. N. (2020). Ustekinumab in psoriasis: Five?year real life experience from a single tertiary centre. Dermatologic Therapy, 33(2). https://doi.org/10.1111/dth.13224

Pugliese, D., Daperno, M., Fiorino, G., Savarino, E., Mosso, E., Biancone, L., Testa, A., Sarpi, L., Cappello, M., Bodini, G., Caprioli, F., Festa, S., Laino, G., Maconi, G., Mazzuoli, S., Mocci, G., Sartini, A., D’Amore, A., Alivernini, S., . . . Armuzzi, A. (2019). Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Digestive and Liver Disease, 51(7), 972–977. https://doi.org/10.1016/j.dld.2019.03.007

Janssen Pharmaceutical Companies. (2024). HIGHLIGHTS OF PRESCRIBING INFORMATION OF STELARA. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf

Daudén, E., Ortiz-Salvador, J. M., Notario, J., Puig, L., Santos-Juanes, J., Herrera-Acosta, E., Gómez-Labrador, L., & Ruiz-Villaverde, R. (2025). Secukinumab for treatment of plaque psoriasis in Real-World clinical practice in Spain: a literature review. Journal of Clinical Medicine, 14(2), 478. https://doi.org/10.3390/jcm14020478

Foley, P., Tsai, T., Rodins, K., Hamadah, I. R., Ammoury, A., Dayem, H. A., Abdallah, M., Crowe, S., Haas, S., Pournara, E., Jagiello, P., & Huang, Y. (2022). Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study. Dermatology and Therapy, 12(2), 511–527. https://doi.org/10.1007/s13555-021-00675-w

Armstrong, A. W., Patil, D., Levi, E., McGuiness, C. B., Wang, X., Wang, Y., Chen, C., Nguyen, E., & Yamauchi, P. S. (2021). Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records. Dermatology and Therapy, 11(5), 1733–1749. https://doi.org/10.1007/s13555-021-00599-5

Novartis Pharmaceuticals Corporation. (2024). HIGHLIGHTS OF PRESCRIBING INFORMATION OF COSENTYX. https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf

Gottlieb, A. B., Burge, R., Malatestinic, W. N., Zhu, B., Zhao, Y., McCormack, J., Kimel, M., & Merola, J. F. (2023). Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program. Dermatology and Therapy, 13(8), 1831–1846. https://doi.org/10.1007/s13555-023-00969-1

Mastorino, L., Dapavo, P., Burzi, L., Rosset, F., Di Corteranzo, I. G., Leo, F., Verrone, A., Stroppiana, E., Ortoncelli, M., Ribero, S., & Quaglino, P. (2023). Drug survival, effectiveness and safety of ixekizumab for moderate?to?severe psoriasis up to 5 years. Journal of the European Academy of Dermatology and Venereology, 38(3), 568–575. https://doi.org/10.1111/jdv.19682

Eli Lilly and Company. (2024). HIGHLIGHTS OF PRESCRIBING INFORMATION OF TALTZ. https://pi.lilly.com/us/taltz-uspi.pdf

Armstrong, A. W., Fitzgerald, T., McLean, R. R., Teeple, A., Uy, J. P., Olurinde, M., Rowland, K., Guo, L., Shan, Y., & Duffin, K. C. (2022). Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ? 2 in the CorEvitas Psoriasis Registry. Dermatology and Therapy, 13(2), 487–504. https://doi.org/10.1007/s13555-022-00865-0

Megna, M., Ruggiero, A., Martora, F., Vallone, Y., Guerrasio, G., & Potestio, L. (2024). Long-Term efficacy and safety of guselkumab in psoriasis patients who failed Anti-IL17: A Two-Year Real-Life study. Journal of Clinical Medicine, 13(9), 2691. https://doi.org/10.3390/jcm13092691

Janssen Biotech, Inc. (2024). HIGHLIGHTS OF PRESCRIBING INFORMATION OF TREMFYA. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf

Orsini, D., Assorgi, C., Bonifati, C., Cameli, N., Graceffa, D., Potestio, L., & Megna, M. (2024). Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study). Journal of Dermatological Treatment, 35(1). https://doi.org/10.1080/09546634.2024.2358150

Orsini, D., Gargiulo, L., Ibba, L., Ingurgio, R. C., Valenti, M., Perugini, C., Pacifico, A., Maramao, F. S., Frascione, P., Costanzo, A., & Narcisi, A. (2023). Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers. Journal of Dermatological Treatment, 34(1). https://doi.org/10.1080/09546634.2023.2220849

Gargiulo, L., Ibba, L., Malagoli, P., Amoruso, F., Argenziano, G., Balato, A., Bardazzi, F., Burlando, M., Carrera, C. G., Damiani, G., Dapavo, P., Dini, V., Franchi, C., Gaiani, F. M., Girolomoni, G., Guarneri, C., Lasagni, C., Loconsole, F., Marzano, A. V., . . . Narcisi, A. (2024). Effectiveness, Tolerability, and drug Survival of Risankizumab in a Real-World setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS). Journal of Clinical Medicine, 13(2), 495. https://doi.org/10.3390/jcm13020495

AbbVie Inc. (2024). HIGHLIGHTS OF PRESCRIBING INFORMATION OF SKYRIZI. https://www.rxabbvie.com/pdf/skyrizi_pi.pdf